CSL Shares Slide After Macquarie Downgrade Amid Growth Concerns
CSL Limited (ASX: CSL) shares tumbled following Macquarie's downgrade from Overweight to Neutral, with the price target slashed by 32% to A$188. The biopharmaceutical giant faces mounting pressure from China's albumin market and intensifying competition in therapies, casting doubt on its medium-term growth prospects.
Despite an ongoing share buy-back program signaling management confidence, broader market sentiment remains negative. Analysts are divided—consensus targets suggest potential upside, but investors await clearer catalysts for 2026 growth. Once a defensive growth darling, CSL now trades NEAR A$180, down mid-30% year-to-date, forcing a reevaluation of whether this represents a buying opportunity or a structural reset.